Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Next generation molecular profiling of malignant rhabdoid tumours
Identifying which are the cellular molecules that drive growth and spread of rhabdoid tumours, and to use this information to nominate new treatment strategies and develop real-time diagnostic tests for personalising treatment
Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
Investigating novel drug combinations for acute myeloid leukaemia
Identifying Combination Therapies Targeting Apoptosis pathways in Paediatric AML (CAuSAL study)
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.
Can we prevent leukaemia in children?
Modelling prophylactic (microbial) prevention of childhood acute lymphoblastic leukaemia
Identifying the support needed by children with sarcoma
Development of a paediatric version of the Sarcoma Assessment Measure (SAM-Paeds): a specific tool for assessing quality of life in children with sarcoma